Beijing, China, December 2006 -- CapitalBio Corporation today announced that it had won the Eighth position in the "Deloitte Technology Fast 500 Asia-Pacific 2006". This came soon after winning the first place of "Deloitte Technology Fast 50 China 2006", November this year.
The Deloitte Technology Fast 500 Asia Pacific Program is recognized as one of the most established and objective ranking programs of fast growing technology companies in the Asia Pacific Region. The program ranks leading public and private companies based on a three-year average percentage for revenue growth. The Asia Pacific tech sector is in very robust shape according to Deloitte´s latest ranking of fast growing technology companies and its survey of their CEO´s. The 500 fastest-growing technology companies in Asia Pacific recorded an average three-year revenue growth of 399 percent and were considered confidently for achieving even higher growth in 2007.
CapitalBio Corporation is a leading total health solution provider that develops and commercializes a broad range of products, including biochip technology products, for drug discovery research, genomics, proteomics, bio-safety testing and clinical applications. CapitalBio has achieved three-year compounded annual growth of 4,229% and is one of the only two Chinese companies in the top ten. For purposes of the ranking, China includes the Chinese Mainland, Hong Kong SAR and Macau SAR.
"It is very exciting to know CapitalBio has achieved the eighth place in Deloitte Technology Fast 500 Asia-pacific 2006", commented Dr. Jing Cheng, CEO & CTO at CapitalBio Corporation. "At CapitalBio we are committed to becoming a technological leader in health and life sciences through providing advanced products and services. Our achievement in the ranking of Deloitte Technology Fast 500 Asia-pacific demonstrates CapitalBio´s position as a pioneer of cutting-edge health solutions in China."